RxDoctor Payments DataLook up a doctor →

David Johnson, MD

Internal Medicine · Searcy, ARNPI 1831154343

Payments from drug & device makers

$630,171in general payments, 2019–2025

Across 1,338 payments — averaging $470.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$451K
  • AbbVie$127K
  • Pfizer$27K
  • GSK$18K
  • AstraZeneca$3K
  • Amgen$1K
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$5,39299%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$630,171 in reported general payments places this provider in the 95th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$95,856
Medicare patients
1,209
Services billed
2,381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide155$147,725
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$72,760
EliquisApixaban110$67,226
Tresiba Flextouch U-200Insulin Degludec87$63,805
CreonLipase/Protease/Amylase13$41,735
FarxigaDapagliflozin Propanediol44$32,555
Breztri AerosphereBudesonide/Glycopyr/Formoterol30$21,102
Humulin R U-500 KwikpenInsulin Regular, Human12$20,337
MounjaroTirzepatide13$17,857
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog25$14,925
JanuviaSitagliptin Phosphate13$14,472
Breo ElliptaFluticasone/Vilanterol29$13,302
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$12,781
JardianceEmpagliflozin23$12,610
LinzessLinaclotide13$10,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,004$147,725155 claims
GSKTrelegy Ellipta, Breo Ellipta$18,055$86,061100 claims
PfizerEliquis$27,005$67,226110 claims
AbbVieCreon, Linzess, Synthroid$127,245$53,89076 claims
AstraZenecaFarxiga, Breztri Aerosphere$3,130$53,65774 claims
Lilly USA, LLCMounjaro$80$17,85713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →